Manish Agrawal

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Death and dignity: dogma disputed
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 360:1997-8. 2002
  2. ncbi request reprint Patients' decision-making process regarding participation in phase I oncology research
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1156, USA
    J Clin Oncol 24:4479-84. 2006
  3. ncbi request reprint Ethics of phase 1 oncology studies: reexamining the arguments and data
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1156, USA
    JAMA 290:1075-82. 2003
  4. ncbi request reprint A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
    Sen H Zhuang
    Cancer Therapeutics Branch, Center of Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer 103:1932-8. 2005
  5. ncbi request reprint Patients' views on financial conflicts of interest in cancer research trials
    Lindsay A Hampson
    Department of Clinical Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 355:2330-7. 2006
  6. ncbi request reprint End-of-life care for terminally ill participants in clinical research
    Manish Agrawal
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, Maryland 20892 1156, USA
    J Palliat Med 5:729-37. 2002
  7. ncbi request reprint Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog
    Manish Agrawal
    Center for Cancer Research, National Cancer Institute Building 10 12C103, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Gynecol Oncol 90:96-9. 2003
  8. ncbi request reprint Voluntariness in clinical research at the end of life
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Cancer Institute NIH, Building 10, Room 1C116, 10 Center Drive, Bethesda, MD 20892 1156, USA
    J Pain Symptom Manage 25:S25-32. 2003
  9. ncbi request reprint Risks and benefits associated with novel phase 1 oncology trial designs
    Shlomo A Koyfman
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA
    Cancer 110:1115-24. 2007
  10. ncbi request reprint Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days
    Jame Abraham
    Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, USA
    J Clin Oncol 21:1866-73. 2003

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Death and dignity: dogma disputed
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 360:1997-8. 2002
  2. ncbi request reprint Patients' decision-making process regarding participation in phase I oncology research
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1156, USA
    J Clin Oncol 24:4479-84. 2006
    ..This study assesses the decision-making process of patients enrolling in phase I oncology studies...
  3. ncbi request reprint Ethics of phase 1 oncology studies: reexamining the arguments and data
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1156, USA
    JAMA 290:1075-82. 2003
    ..Overall, it appears that phase 1 oncology trials satisfy the requirement for a favorable risk-benefit ratio and that patients who enroll provide adequate informed consent...
  4. ncbi request reprint A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
    Sen H Zhuang
    Cancer Therapeutics Branch, Center of Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer 103:1932-8. 2005
    ..The authors conducted a Phase I study by administering ixabepilone to patients as a 1-hour intravenous infusion daily for 3 consecutive days every 21 days...
  5. ncbi request reprint Patients' views on financial conflicts of interest in cancer research trials
    Lindsay A Hampson
    Department of Clinical Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 355:2330-7. 2006
    ..Financial ties between researchers or medical centers and companies whose drugs are being tested have come under increasing scrutiny...
  6. ncbi request reprint End-of-life care for terminally ill participants in clinical research
    Manish Agrawal
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, Maryland 20892 1156, USA
    J Palliat Med 5:729-37. 2002
    ....
  7. ncbi request reprint Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog
    Manish Agrawal
    Center for Cancer Research, National Cancer Institute Building 10 12C103, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Gynecol Oncol 90:96-9. 2003
    ..This report describes results with BMS-247550, an epothilone B analog that stabilizes microtubules, with activity in previously treated adenocarcinoma of the cervix...
  8. ncbi request reprint Voluntariness in clinical research at the end of life
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Cancer Institute NIH, Building 10, Room 1C116, 10 Center Drive, Bethesda, MD 20892 1156, USA
    J Pain Symptom Manage 25:S25-32. 2003
    ..Finally, correctly characterized threats to voluntariness are examined and ways to ameliorate them are presented...
  9. ncbi request reprint Risks and benefits associated with novel phase 1 oncology trial designs
    Shlomo A Koyfman
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA
    Cancer 110:1115-24. 2007
    ..The prevalence of several novel trial designs and their association with a variety of clinical endpoints was evaluated...
  10. ncbi request reprint Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days
    Jame Abraham
    Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, USA
    J Clin Oncol 21:1866-73. 2003
    ..BMS-247550 is a semisynthetic analog of the natural product epothilone B. We conducted a phase I study administering BMS-247550 as a 1-hour intravenous infusion daily for 5 consecutive days every 21 days...
  11. ncbi request reprint Attending to psychologic symptoms and palliative care
    Manish Agrawal
    J Clin Oncol 20:624-6. 2002